Potential side effects of 5AR inhibitors like finasteride and dutasteride. Users debate risks, benefits, and personal experiences with these hair loss treatments.
28M shares hair transplant results 6 months after 3633 grafts via FUE by Dr. Rahal in Ottawa, costing ~$24k CAD. Users discuss the impressive results, procedure experience, and cost breakdown.
The user experienced continuous hair shedding for 16 months while on finasteride, with periods of improvement. They also used T Gel shampoo and noticed a reduction in hair loss symptoms after 18 months, including the return of their sex drive and normal hair texture.
Hair loss treatments discussed include finasteride, minoxidil, and dermarolling. Users advise patience, noting initial shedding is common and treatments take time to show results.
Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.
A user shared their 6-month progress with hair loss treatment, showing significant improvement. They used 1mg Propecia daily, Rogaine foam (5% minoxidil) after morning showers, and CG210 spray before bedtime.
Fighting hair loss with "The Big 3" treatments of Propecia, Rogaine and Nizoral shampoo, as well as specific advice on how to use these products. People have shared their long-term success stories and some have discussed the side effects of finasteride. Other suggestions included Lipogaine and Pura D'or Hair Loss Prevention Therapy Shampoo & Conditioner.
HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
A 20-year-old started using minoxidil, rosemary oil, Alpecin caffeine shampoos, scalp massager, derma rollers, and supplements for hair regrowth, seeing significant improvement initially. However, after 6 months, they noticed increased shedding and thinning, causing concern about whether this is normal or indicative of a problem.
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
Hair follicles can potentially produce more hair strands with treatments like Minoxidil and finasteride. Notable improvements in hair density are possible, but achieving multiple strands per follicle is uncertain.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
A user who underwent a hair transplant in their twenties and are now discussing the best treatments for long-term management of hair loss, such as finasteride and Minoxidil, as well as potential alternative treatment options like RU58841.
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
The conclusion of the conversation is that the user should consider using treatments such as finasteride, minoxidil, and RU58841 to potentially reverse their hair loss. Other suggestions include using hair loss concealers and maintaining a healthy diet.
The user shared progress pictures showing hair regrowth after using minoxidil, finasteride, and dermarolling, and is currently trying oral minoxidil, dutasteride, and a finasteride/minoxidil topical. Another user commented on the significant improvement, and the original poster emphasized the importance of consistency despite shedding phases.
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
The user switched from finasteride to dutasteride after experiencing significant hair shedding, and is also using oral minoxidil. Dutasteride helped stop the shedding, but it's too early to determine if it will reverse hair loss.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
A user shared their excitement about starting finasteride for hair loss after trying various ineffective methods. Other users discussed their experiences with finasteride, including shedding phases and side effects, with one mentioning using topical finasteride and minoxidil.
A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
A 19-year-old experiencing severe hair loss since 16 is using a treatment regimen of 5% minoxidil, 0.1% finasteride topical solution, 3% procapil hair serum, and 0.5 mg dutasteride daily. They are concerned about the effectiveness and potential shedding phase, with advice suggesting noticeable changes in 6 to 8 months.
The conversation discusses the availability of GT20029, a new topical hair loss treatment with fewer side effects than Minoxidil or finasteride. Users suggest using finasteride to preserve hair until GT20029 becomes available.
If you stop taking finasteride after 10 years, hair loss will resume at the rate it would have without treatment. Minoxidil cessation can cause immediate and significant shedding.
A user shared progress pictures showing improvement from NW6 diffuse to NW1 after 5 months of finasteride and 2 months of dutasteride. Another user asked if these treatments affected beard or body hair thickness.